With the generic cliff receding, R&D pipelines continuing to improve and FDA approvals of biopharmaceuticals up, opportunities outweigh the risks for investors in the biopharmaceuticals industry. The key for the industry going forward will be to continue to improve R&D productivity and commercialize drugs that represent a true advance to current treatment.
Image Courtesy of jscreationzs / FreeDigitalPhotos.net
